ReviewCurrent atherosclerosis reports2020
Lipoprotein(a) and Its Potential Association with Thrombosis and Inflammation in COVID-19: a Testable Hypothesis.
Review in Current atherosclerosis reports, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 53 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
53 citing papers in PubMed, 71 citations in OpenAlex.
- Lipoprotein(a) and Benefit of PCSK9 Inhibition in Patients With Nominally Controlled LDL Cholesterol.Journal of the American College of Cardiology · 2021Trial
- Temporal Proteomic Profiling of Hospitalized COVID-19 Patients Reveals Prognostic Biomarkers.Journal of proteome research · 2026Article
- Article
- Cell apoptosis in ischemic stroke: Focus on lipid metabolism.Neural regeneration research · 2026Article
- Diagnostic and Severity Assessment of Coronary Artery Disease Using ApoB/ApoA-I Ratio: Insights from a Statin-Treated Eastern European Cohort.Medicina (Kaunas, Lithuania) · 2026Article
- Metabolic implications of COVID-19 with a focus on lipid profiles and inflammatory markers.Scientific reports · 2026Article
- 2024: The year in cardiovascular disease - the year of lipoprotein(a). Research advances and new findings.Archives of medical science : AMS · 2025Article
- Lipoprotein(a) and cardiovascular disease.The Biochemical journal · 2024Review
- New data allow to better understand the secrets of lipoprotein(a): is that for sure?European heart journal open · 2024Article
- Association of COVID-19 With Emergence of Comorbidities: A Hospital-Based Cohort Study.Cureus · 2024Article
- Genetics and Pathophysiological Mechanisms of Lipoprotein(a)-Associated Cardiovascular Risk.Journal of the American Heart Association · 2024Review
- High lipoprotein(a): Actionable strategies for risk assessment and mitigation.American journal of preventive cardiology · 2024Review
- Lipoprotein(a) and Atherosclerotic Cardiovascular Disease: Where Do We Stand?International journal of molecular sciences · 2024Review
- Lipoprotein(a): Levels and Reference Intervals Among People in Saudi Arabia.Diabetes, metabolic syndrome and obesity : targets and therapy · 2024Article
- The effect of rosuvastatin alone or in combination with fenofibrate or omega-3 fatty acids on lipoprotein(a) levels in patients with mixed hyperlipidemia.Archives of medical sciences. Atherosclerotic diseases · 2024Article
- Epidemiology, pathogenesis, and management of Coronavirus disease 2019-associated stroke.Frontiers of medicine · 2023Review
- Lipoprotein(a), Interleukin-6 inhibitors, and atherosclerotic cardiovascular disease: Is there an association?Atherosclerosis plus · 2023Review
- Plasma tissue-type plasminogen activator is associated with lipoprotein(a) and clinical outcomes in hospitalized patients with COVID-19.Research and practice in thrombosis and haemostasis · 2023Article
- Lipoprotein(a): A New Intensive Care Unit Admission Predictor in Coronavirus Disease 2019 Patients.Thoracic research and practice · 2023Article
- Lipoprotein(a) Does Not Predict Thrombotic Events and In-Hospital Outcomes in Patients with COVID-19.Journal of clinical medicine · 2023Article
Corrections and comments
- Commented on by
Authors and funding
6 authors at 4 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purpose of reviewThe COVID-19 pandemic has infected over > 11 million as of today people worldwide and is associated with significant cardiovascular manifestations, particularly in subjects with preexisting comorbidities and cardiovascular risk factors. Recently, a predisposition for arterial and venous thromboses has been reported in COVID-19 infection. We hypothesize that besides conventional risk factors, subjects with elevated lipoprotein(a) (Lp(a)) may have a particularly high risk of developing cardiovascular complications. RECENT
findingsThe Lp(a) molecule has the propensity for inhibiting endogenous fibrinolysis through its apolipoprotein(a) component and for enhancing proinflammatory effects such as through its content of oxidized phospholipids. The LPA gene contains an interleukin-6 (IL-6) response element that may induce an acute phase-type increase in Lp(a) levels following a cytokine storm from COVID-19. Thus, subjects with either baseline elevated Lp(a) or those who have an increase following COVID-19 infection, or both, may be at very high risk of developing thromboses. Elevated Lp(a) may also lead to acute destabilization of preexisting but quiescent atherosclerotic plaques, which might induce acute myocardial infarction and stroke. Ongoing studies with IL-6 antagonists may be informative in understanding this relationship, and registries are being initiated to measure Lp(a) in subjects infected with COVID-19. If indeed an association is suggestive of being causal, consideration can be given to systematic testing of Lp(a) and prophylactic systemic anticoagulation in infected inpatients. Therapeutic lipid apheresis and pharmacotherapy for the reduction of Lp(a) levels may minimize thrombogenic potential and proinflammatory effects. We propose studies to test the hypothesis that Lp(a) may contribute to cardiovascular complications of COVID-19.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.